中文     English
Rani Therapeutics will receive US $5,000,000 ( 30 million RMB) from KPC Pharmaceuticals (600422)for its series C financing

 

 KPC Pharmaceuticals has signed an investment agreement with Rani Therapeutics. Under this agreement, Rani Therapeutics will receive US $5,000,000 (30 million RMB) from KPC Pharmaceuticals 600422for its series C financing. Until 31st May, 2015, the total asset of Rani Therapeutics was 158,534,600 RMB (US $26.33 million). As a healthcare technology innovation company, Rani Therapeutics, the subsidiary of InCube Labs, is focusing on researching and commercializing robot tablets.

 

For more information, please contact us at david.chen@bfcgroup.biz